1,3,4-oxadiazol-2-ones as PPAR delta

Details for Australian Patent Application No. 2005230838 (hide)

Owner Aventis Pharmaceuticals Inc.

Inventors McGarry, Daniel G.; Keil, Stefanie; Merrill, Jean; Goerlitzer, Jochen; Wendler, Wolfgang; Chandross, Karen

Agent Watermark

Pub. Number AU-A-2005230838

PCT Pub. Number WO2005/097763

Priority 60/558,420 01.04.04 US

Filing date 30 March 2005

Wipo publication date 20 October 2005

International Classifications

A61K 31/4245 (2006.01) - Oxadiazoles

C07D 413/12 (2006.01) Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms

C07D 417/12 (2006.01) Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group

Event Publications

26 October 2006 PCT application entered the National Phase

  PCT publication WO2005/097763 Priority application(s): WO2005/097763

27 October 2011 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(d). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005230840-Low density light weight filament and fiber

2005230837-1,3,4-oxadiazol-2-ones as PPAR delta modulators